AU1912000A - Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway - Google Patents

Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway

Info

Publication number
AU1912000A
AU1912000A AU19120/00A AU1912000A AU1912000A AU 1912000 A AU1912000 A AU 1912000A AU 19120/00 A AU19120/00 A AU 19120/00A AU 1912000 A AU1912000 A AU 1912000A AU 1912000 A AU1912000 A AU 1912000A
Authority
AU
Australia
Prior art keywords
stimulation
signaling pathway
cytoplasmic domain
domain signaling
angiogenesis via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19120/00A
Inventor
Arie Horowitz
Michael Simons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/190,976 external-priority patent/US6815187B1/en
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU1912000A publication Critical patent/AU1912000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU19120/00A 1998-11-12 1999-11-10 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway Abandoned AU1912000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/190,976 US6815187B1 (en) 1998-02-04 1998-11-12 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway
US09190976 1998-11-12
PCT/US1999/026647 WO2000027416A1 (en) 1998-11-12 1999-11-10 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway

Publications (1)

Publication Number Publication Date
AU1912000A true AU1912000A (en) 2000-05-29

Family

ID=22703583

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19120/00A Abandoned AU1912000A (en) 1998-11-12 1999-11-10 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway

Country Status (4)

Country Link
EP (1) EP1131081A4 (en)
AU (1) AU1912000A (en)
CA (1) CA2349720A1 (en)
WO (1) WO2000027416A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004028A1 (en) * 2000-07-06 2002-01-17 The General Hospital Corporation Methods of modulating wound healing and angiogenesis
HU0800464D0 (en) * 2008-07-24 2008-09-29 Szilak Labor Bioinformatikai E Syndecan-4 a modulator of rac1-gtp
ES2645431T3 (en) * 2012-07-06 2017-12-05 Innovative Technologies In Biological Systems S.L. Fluorescent fusion polypeptide, biosensor comprising said polypeptide and uses thereof

Also Published As

Publication number Publication date
CA2349720A1 (en) 2000-05-18
EP1131081A1 (en) 2001-09-12
EP1131081A4 (en) 2006-09-06
WO2000027416A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
AU5151100A (en) Extracellular signaling molecules
AU3898999A (en) Aloe pectins
AU5558099A (en) One-step threaded implant
AU5274499A (en) Therapeutic chemokine receptor antagonists
AU2497597A (en) Inhibition of asbnormal accumulation of extracellular matrices
AU4698299A (en) 5-HT7 receptor antagonists
AU2753500A (en) Uses of thank, a tnf homologue that activates apoptosis
EP1063990A4 (en) Therapy of estrogen-associated disorders
TW563521U (en) Sanitary pad
EA199900303A3 (en) Carbazol derivatives
AU2676799A (en) Modulation of hedgehog-mediated signaling pathway
AU4817200A (en) Death domain containing receptor 5
AU4425399A (en) Novel therapeutic agents that modulate 5-ht receptors
AUPP698998A0 (en) Shower cubicle
AU4984300A (en) Death domain containing receptor 4
AU1912000A (en) Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway
AU3668499A (en) Human receptor molecules
AU5918598A (en) Human extracellular matrix-1
AU5446499A (en) Apoptosis inducing agents
AU4176797A (en) Personal hygienic device
AU2162000A (en) Seven transmembrane domain receptor zsig56
AU1531901A (en) Human tnf receptor
EP1100813A4 (en) HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb
GB2377959B (en) Removable nonmetallic bridge plug or packer
AU8281398A (en) Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase